Suppr超能文献

滤泡性淋巴瘤的细胞治疗:自体造血干细胞移植、异基因造血干细胞移植和嵌合抗原受体 T 细胞治疗。

Cellular Therapy in Follicular Lymphoma: Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, and Chimeric Antigen Receptor T-cell Therapy.

机构信息

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK.

Department of Haemato-Oncology, St Bartholomew's Hospital, London, UK.

出版信息

Hematol Oncol Clin North Am. 2020 Aug;34(4):701-714. doi: 10.1016/j.hoc.2020.02.006. Epub 2020 Apr 16.

Abstract

A subset of follicular lymphoma patients with high-risk clinical features continues to pose a therapeutic challenge. Hematopoietic stem cell transplantation is a suitable consolidative treatment option for these patients. Data on chimeric antigen receptor T-cell therapy are promising in relapsed/refractory and transformed patients. The increasing armamentarium of nontransplant options coupled with the associated potential long-term sequelae of transplantation raises questions about the placement of transplant strategies in the follicular lymphoma treatment hierarchy.

摘要

一部分滤泡性淋巴瘤患者具有高危临床特征,这仍然是一个治疗挑战。造血干细胞移植是这些患者合适的巩固治疗选择。嵌合抗原受体 T 细胞疗法在复发/难治性和转化患者中的数据很有前景。非移植选择的手段不断增加,加上移植相关的潜在长期后果,这引发了关于滤泡性淋巴瘤治疗分层中移植策略定位的问题。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验